The agreement provides Premier members with access to DermaPure human dermal allograft featuring dCELL technology for the treatment of complex, acute and chronic wounds.

Antony Odell, CEO, Tissue Regenix Group plc commented: “Approval by Premier marks a significant step for DermaPure.

This confirms the unique characteristics of our patented dCELL® technology, the powerful clinical evidence we have collected and the remarkable outcomes it achieves in real world clinical situations.”

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®‘) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts.

The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.